Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis
Conditions
Interventions
Secukinumab
Placebo
Locations
77
United States
Novartis Investigative Site
Aventura, Florida, United States
Novartis Investigative Site
Palm Harbor, Florida, United States
Novartis Investigative Site
Sarasota, Florida, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Bowling Green, Kentucky, United States
Novartis Investigative Site
St Louis, Missouri, United States
Start Date
April 10, 2014
Primary Completion Date
May 27, 2015
Completion Date
March 28, 2018
Last Updated
April 16, 2019
NCT07486960
NCT07536529
NCT07295509
NCT07286058
NCT06100744
NCT04402086
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions